Deciphera Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Deciphera Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).

21 total trials 6 currently recruiting 6 completed early-phase tilt top decile by trial count

Deciphera Pharmaceuticals: 21 sponsored US clinical trials, 6 recruiting.

Deciphera Pharmaceuticals sponsors 21 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tenosynovial Giant Cell Tumor, with 3 trials.

Top-decile sponsor footprint

Deciphera Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

6 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (60.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

21 total, page 1 of 1

RECRUITING Phase 1

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090
RECRUITING

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

NCT07075471
RECRUITING Phase 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

NCT06966024
RECRUITING Phase 1

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

NCT06630234
RECRUITING Phase 2

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561
RECRUITING Phase 1

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT05957367
ACTIVE NOT RECRUITING Phase 3

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105
ACTIVE NOT RECRUITING Phase 3

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262
ACTIVE NOT RECRUITING Phase 1

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

NCT04892017
ACTIVE NOT RECRUITING Phase 3

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501
ACTIVE NOT RECRUITING Phase 1

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT03069469
COMPLETED Phase 1

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

NCT07158411
COMPLETED Phase 1

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

NCT07158398
TERMINATED Phase 1

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

NCT06287463
COMPLETED Phase 1

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

NCT04530981
TERMINATED Phase 1

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

NCT03717415
TERMINATED Phase 1

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

NCT03601897
COMPLETED Phase 3

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

NCT03353753
COMPLETED Phase 1

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

NCT02571036
TERMINATED Phase 1

A Study of DCC-2701 in Participants With Advanced Solid Tumors

NCT02228811
COMPLETED Phase 1

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

NCT00827138

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 1
Phase 3 4

Therapeutic Areas

Tenosynovial Giant Cell Tumor 3
Tenosynovial Giant Cell Tumor, Diffuse 2
Giant Cell Tumor of Tendon Sheath 2
Pigmented Villonodular Synovitis 2
GIST 2
GIST - Gastrointestinal Stromal Tumor 1
Tenosynovial Giant Cell Tumor, Localized 1
Advanced Malignant Neoplasm 1
Castration-resistant Prostate Cancer 1
Chronic Graft-versus-host Disease (cGVHD) 1

What is open in the Deciphera Pharmaceuticals pipeline

6 recruiting of 21 indexed (29% open); 6 completed (29%).

Phase mix: 4 late (III/IV) vs 16 early (I/II) (early-phase heavy).

Top condition: Tenosynovial Giant Cell Tumor (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Deciphera Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 21 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Deciphera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Deciphera PharmaceuticalsAEterna ZentarisAmphastar PharmaceuticalsApellis PharmaceuticalsArray Biopharma, now a wholly owned subsidiary of Pfizer89bioAlabama Physical Therapy & AcupunctureAlloSourceAlnylam Pharmaceuticals
Deciphera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Deciphera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 21 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Deciphera Pharmaceuticals page

21 registered trials is a research-attention snapshot, not an endorsement of Deciphera Pharmaceuticals or any single study.

  • 6 of Deciphera Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Tenosynovial Giant Cell Tumor is the condition Deciphera Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tenosynovial Giant Cell Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Deciphera Pharmaceuticals pipeline card: 21 registered trials from official public datasets.Report a data error.